
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is a promising biotechnology company with a strong pipeline of potential drug candidates targeting the Wnt pathway in a wide variety of retinal and vascular diseases. Preclinical studies have shown promising results for lead candidate SZN-8141 in reducing avascular and pathological neovascular tuft areas, as well as vascular leakage, which could be critical factors for potential adoption and differentiation. The company's strategic partnerships and milestone achievements also provide support for continued pipeline development. Surrozen's strong cash position and anticipated financing tranche further demonstrate its commitment to advancing its potentially revolutionary treatments.
Bears say
Surrozen is a clinical-stage biotech company that specializes in developing therapeutics for eye diseases using the Wnt signaling pathway. Despite the development milestones and upcoming presentations at conferences, there is a concern that the company's R&D expenses of $29.4M and net loss of $242.0M for FY25 may continue to impact its financials. Additionally, there is a risk that the Wnt agonist class may not be successful in the treatment of retinal diseases, affecting the perception of the company's products and potentially leading to failure in securing necessary funding and resources for future operations.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares